Company Profile

Advanced Genetic Systems Inc (AKA: AGS)
Profile last edited on: 12/26/22      CAGE: 8AME5      UEI: EKBRFLASKNF4

Business Identifier: RNP based therapy
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1554 25th Avenue
San Francisco, CA 94122
Location: Single
Congr. District: 12
County: San Francisco

Public Profile

Advanced Genetic Systems, Inc. (AGS) is a drug discovery company dedicated to pioneering novel classes of antiviral therapeutics. AGS has focused our drug discovery efforts on an under-explored target, the Ribonucleoprotein (RNP) complex. RNPs are composed of interactions between structural RNA and proteins. Targeting RNPs is challenging due to the multiple roles, dynamic conformations, and chemical instability of these complexes. To address these challenges, we have developed two key tools. First, AGS has built a robust cell-based screening platform dedicated to targeting this class of interaction. Second, AGS has developed novel chemical strategies including the assembly and screening of custom libraries tailored to the chemistry of RNPs. AGS is developing an entirely new class of HIV therapeutic that is inherently less vulnerable to escape mutations by the virus, but can also be combined with other drugs to maintain effective treatment and enhance quality of life.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2015 1 NIH $277,424
Project Title: Mechanistic Studies of a Novel Small Molecule Hiv Inhibitor
2013 1 NIH $279,588
Project Title: Virology Studies Of A Small Molecule Hiv Rev Inhibitor
2010 2 NIH $847,700
Project Title: Identification of Anti-Hiv Lead Compounds Targeting Rev
2008 1 NIH $238,974
Project Title: A small molecule screen to target viral RNA-protein complexes
2006 2 NIH $920,375
Project Title: Genetic Assay for Inhibitors of RNA-Protein Interactions

Key People / Management

  Robert Nakamura -- President

  Alan D Frankel -- Founder

  Adam Robert Renslo

Company News

There are no news available.